GI Insights

Are there fewer physician-scientists today than there were a few decades ago? What does the future landscape look like for medical research? Dr. Mark Donowitz, LeBoff Professor of Medicine and director of the Center for Epithelial Disorders at the Johns Hopkins University School of Medicine, as well as immediate past-president of the American Gastroenterological Association, discusses some of the barriers and challenges physician-scientists face, and how we can ensure a sound future for research. Dr. Mark DeLegge hosts.

How common is Barrett's esophagus in patients with chronic gastroesophageal reflux disease (GERD) or asymptomatic reflux? What risk factors might predict a diagnosis of Barrett's esophagus? Dr. Donald Castell, professor of medicine and director of the esophageal disorder program at the Medical University of South Carolina, joins host Dr. Mark DeLegge to discuss this potentially pre-cancerous condition.

Constipation is a common symptom that presents more often in women and as patients get older. What are the primary and secondary causes of chronic constipation? What are some of the differentiating factors between chronic constipation and IBS-C? Dr. David Peura, professor of medicine at the University of Virginia School of Medicine, joins host Dr. Mark DeLegge to discuss algorithms for diagnosing chronic constipation. When are lifestyle changes not enough for treating chronic constipation, and what are the most effective alternatives?

Acetaminophen, vitamin supplements and antibiotics are just a few of the medications that can cause liver injury. What are the signs of drug-induced liver injury? Are the effects immediate, or do the effects become noticeable after an extended period of time? Dr. Rowen Zetterman, professor of internal medicine at the University of Nebraska Medical Center, provides an overview of factors that might lead to drug-induced liver injury. Dr. Mark DeLegge hosts.

Are there fewer physician-scientists today than there were a few decades ago? What does the future landscape look like for medical research? Dr. Mark Donowitz, LeBoff Professor of Medicine and director of the Center for Epithelial Disorders at the Johns Hopkins University School of Medicine, as well as immediate past-president of the American Gastroenterological Association, discusses some of the barriers and challenges physician-scientists face, and how we can ensure a sound future for research. Dr. Mark DeLegge hosts.

How common is Barrett's esophagus in patients with chronic gastroesophageal reflux disease (GERD) or asymptomatic reflux? What risk factors might predict a diagnosis of Barrett's esophagus? Dr. Donald Castell, professor of medicine and director of the esophageal disorder program at the Medical University of South Carolina, joins host Dr. Mark DeLegge to discuss this potentially pre-cancerous condition.

What does outcomes research measure, and how does it differ from clinical trials? Is evidence-based medicine related to outcomes research? Host Dr. Jay Goldstein evaluates outcomes research with Dr. Glenn Eisen, professor in the department of medicine and the division of gastroenterology at Oregon Health and Science University. How will outcomes research impact clinical practices?

Untreated hepatitis B can lead to cirrhosis and liver cancer. What methods are available for physicians to treat hepatitis B patients? Host Dr. Jay Goldstein reviews available treatments for reducing liver damage from hepatitis B with Dr. Scott Cotler, chief of hepatology at the University of Illinois at Chicago. How can the virus be suppressed while reducing the progression of liver disease?

What does outcomes research measure, and how does it differ from clinical trials? Is evidence-based medicine related to outcomes research? Host Dr. Jay Goldstein evaluates outcomes research with Dr. Glenn Eisen, professor in the department of medicine and the division of gastroenterology at Oregon Health and Science University. How will outcomes research impact clinical practices?

Untreated hepatitis B can lead to cirrhosis and liver cancer. What methods are available for physicians to treat hepatitis B patients? Host Dr. Jay Goldstein reviews available treatments for reducing liver damage from hepatitis B with Dr. Scott Cotler, chief of hepatology at the University of Illinois at Chicago. How can the virus be suppressed while reducing the progression of liver disease?